J4I.F GRAFT POLYMER UK LS -001
- Market cap
- EUR 6.81M
- P/E
- -
- P/B
- 1.37x
- ROE
- -92.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending May 2026.
Is J4I.F undervalued?
Graham numberThe Graham number of GRAFT POLYMER UK LS -001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GRAFT POLYMER UK LS -001 fundamental analysis
No fundamental analysis for GRAFT POLYMER UK LS -001 yet.
GRAFT POLYMER UK LS -001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GRAFT POLYMER UK LS -001
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product consists of SVN-114 for the treatment of post-traumatic …
Full company profileGRAFT POLYMER UK LS -001 financial statements
GRAFT POLYMER UK LS -001 annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 520K | 542K | 587K | 0.00 | 0.00 |
| Gross Profit | 490K | 300K | 258K | 0.00 | - |
| Operating Income | -442K | -2.69M | -2.21M | -1.51M | -3.58M |
| EBITDA | - | -2.59M | -2.94M | -1.38M | -5.74M |
| Net Income | -451K | -2.71M | -3.12M | -1.59M | -5.74M |
| EPS | - | -0.03 | -0.03 | 0.00 | 0.00 |
| Balance Sheet | |||||
| Total Assets | - | 4.94M | 2.43M | 3.20M | 7.59M |
| Total Liabilities | - | 385K | 408K | 119K | 1.39M |
| Shareholders' Equity | - | 4.55M | 2.03M | 3.08M | 6.19M |
| Cash & Short-term Investments | - | 1.64M | 155K | 757K | 1.72M |
| Cash Flow | |||||
| Operating Cash Flow | -166K | -2.36M | -1.24M | -1.13M | -3.27M |
| Capital Expenditure | 15.0K | 718K | 232K | 4.00K | 0.00 |
| Free Cash Flow | -181K | -3.08M | -1.47M | -1.13M | -3.27M |
| Ratios | |||||
| ROE | - | -59.4% | -154.0% | -51.6% | -92.7% |
| ROA | - | -54.8% | -128.2% | -49.6% | -75.7% |
| Net Profit Margin | -86.7% | -499.1% | -531.5% | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
GRAFT POLYMER UK LS -001 dividends
GRAFT POLYMER UK LS -001 has not paid dividends in the last 5 fiscal years.
Who owns GRAFT POLYMER UK LS -001
- Insiders 26.44%
- Institutions 1.88%
- Public & others 71.69%
- Shares outstanding 6.81B
- Free float 5.11B
GRAFT POLYMER UK LS -001 company profile
- Company name
- GRAFT POLYMER UK LS -001
- Ticker
- J4I.F
- ISIN
- GB00BMD1Z199
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Machinery
- Employees
- 6
- Fiscal year end
- May
- Address
- Eccleston Yards, London, United Kingdom, SW1W 9NF
- Phone
- 44 77 9543 0246
- Website
- solvonis.com
About GRAFT POLYMER UK LS -001
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product consists of SVN-114 for the treatment of post-traumatic stress disorder; and SVN-015 for the treatment of stimulant use disorder. The company was formerly known as Graft Polymer (UK) Plc and changed its name to Solvonis Therapeutics plc in January 2025. Solvonis Therapeutics plc was incorporated in 2017 and is headquartered in London, the United Kingdom.
GRAFT POLYMER UK LS -001 management
4- Mr. Anthony James TennysonCEO & Executive Director · born 1976
- Mr. Victor BolduevFounder · born 1957
- Mr. Ryan Paul NeatesChief Financial Officer · born 1991
- Dr. David John Nutt DM, FMedSci, FRCP, FRCPsych, FSB, Ph.D.Chief Scientific Advisor